HSV

DGAP-News: AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

Retrieved on: 
Thursday, September 1, 2022
MSD, Powerhouse, Patient, Risk management, Drug of last resort, SPAC, Transplant, Hematopoietic stem cell transplantation, CEO, HBV, Hepatitis B virus, Business plan, Virus, BK virus, Infection, Pritelivir, Â, Board, HSV, AMR, PIPE, CFO, Leadership, Cytomegalovirus, Nasdaq, Company, BKV, BK, Immunodeficiency, CMV, Biochemistry, Sepsis, Capital market, Merck, Heike Brötz-Oesterhelt, Merck & Co., Management, Security (finance), Pharmaceutical industry, EU, Bayer

AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

Key Points: 
  • AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer
    The issuer is solely responsible for the content of this announcement.
  • AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer
    Wuppertal, Germany, September 1, 2022 - AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, today announced the appointment of Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer (CFO), effective September 1, 2022.
  • Dr. Stefan Oschmann, Chairman of the Board of AiCuris, said: It is my pleasure to welcome Dr. Sabrina Kuttruff-Coqui as our new CFO.
  • Dr. Sabrina Kuttruff-Coqui, newly appointed CFO of AiCuris, commented: I am thrilled to join the AiCuris team at this crucial stage of development.

Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

Retrieved on: 
Wednesday, August 10, 2022
National Institute of Allergy and Infectious Diseases, U.S. Securities and Exchange Commission, HIV/AIDS, Association, American Association, Medical laboratory, RNA transfection, GLOBE, University of Washington Department of Global Health, Diagnosis, National Center for Advancing Translational Sciences, HIV Vaccine Trials Network, HVTN, Cancer, Leadership, Fred Hutchinson Cancer Research Center, National Institute, Infection, Board, Society, Research, NIAID, Security (finance), HSV, Vaccine, COVID-19, HSV-2, Biotechnology, Alumnus, Virology, Degenerative disease, University, Board of directors, HIV, American Association of Clinical Endocrinologists, Immune system, Pharmaceutical industry, Science, Medicine, Director, Gritstone

EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.

Key Points: 
  • EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.
  • Effective August 12, 2022, Dr. Corey replaces Richard Heyman, Ph.D. who stepped down as a Board Member after more than six years of service.
  • I would also like to sincerely thank Rich Heyman for his years of service on Gritstones Board of Directors, where he helped us develop and apply our novel platform technologies.
  • We are thrilled to have Larry join us to help guide continued advancement of Gritstones important clinical programs and unique scientific capabilities, said Dr. Elaine V. Jones, Chair of Gritstone bios Board of Directors.

Global Genital Herpes Treatment Market Outlook Report 2022-2027 Featuring Key Vendors - GlaxoSmithKline, Glenmark Pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, & Bausch Health Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Infectious Diseases, Pharmaceutical, Health, People, FDA, LGBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, Ageing, Valaciclovir, Pharmacy, Retail, Risk, MSM, Famciclovir, Recurrence, Sex organ, Food, Simplex, Population, NE, Geography, GSK, Incidence, IND, Man, HSV, Patient, HSV-2, Company, Genital herpes, Vaccine, STD, OTC, Infection, Awareness, Immunodeficiency, Sanofi, Herpes labialis, WHO, Technology, Herpes simplex virus, HIV, Factor X, Sex, STI, Vertically transmitted infection, Investigational New Drug, Pharmaceutical industry, Birth control, Aciclovir, Aciclovir, Pritelivir, Moderna

The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
  • HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes.
  • North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%.

Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, August 4, 2022
Private Securities Litigation Reform Act, Security (finance), Good manufacturing practice, Annual report, COVID-19, Good, LNP, Transgene, Neoplasm, Investor, American Association for Cancer Research, RNA, Public expenditure, Patient, Food, GMP, Association, Nasdaq, U.S. Securities and Exchange Commission, Safety, HSV, IND, RNA transfection, AACR, American Association, Risk, Research, Investment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Therapy, Achievement, GLOBE, Â, Mark (given name), Immunotherapy, SEC, Growth, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported financial results for the second quarter of 2022 and highlighted recent achievements and developments.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported financial results for the second quarter of 2022 and highlighted recent achievements and developments.
  • On track to report combination data and additional monotherapy data for ONCR-177 in the second half of 2022.
  • Research and development expenses for the quarter ended June 30, 2022 were $12.5 million compared to $10.7 million for the corresponding quarter in 2021.
  • General and administrative expenses for the quarter ended June 30, 2022 were $6.2 million compared to $4.9 million for the corresponding quarter in 2021.

Candel Therapeutics Appoints Three New Members to its Board of Directors

Retrieved on: 
Monday, August 1, 2022
CFO, KPMG, CADL, Perrigo, Bausch Health, Chief executive officer, Company, Public, Transaction, Immunogenic cell death, Acquisition, Doctor of Philosophy, Â, Research, Accounting, American Society for Biochemistry and Molecular Biology, Cancer, Virology, Smith & Nephew, Actavis, Growth, HIV, Society, SARS, IPO, GLOBE, Board, CEO, SEC, Harvard Business School, Institute, Novartis, Organization, Bausch & Lomb, Cardinal Health, Science, Biochemistry, Loyola Marymount University, Molecular biology, Vaccine, Network for Excellence in Health Innovation, HSV, Private Securities Litigation Reform Act, National academy, Therapy, BS, Leadership, Senior, Patient, Certified Public Accountant, Market for corporate control, Eko, Management, Pharmaceutical industry, Fellow of the Academy of Medical Sciences, Chikungunya, Sanofi, Candel, MD

These new members replace current Board members: Alan E. Smith, PhD, Shaan Ghandi, MD, D.Phil, and Udi Meirav, PhD, maintaining Candels nine-seat board.

Key Points: 
  • These new members replace current Board members: Alan E. Smith, PhD, Shaan Ghandi, MD, D.Phil, and Udi Meirav, PhD, maintaining Candels nine-seat board.
  • We are pleased to welcome Renee, Gary, and Joseph, preeminent leaders in their respective fields, as new directors to the Candel Board, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) at Candel.
  • Dr. Nabel co-founded ModeX Therapeutics and held the position of President and CEO before its acquisition by OPKO in May 2022.
  • In July 2022, he stepped down as chair of Bausch + Lombs Board and will remain CEO until his successor is appointed.

DeciBio Ventures Invests in Replay’s $55M seed funding round led by KKR & Co. and OMX Ventures

Retrieved on: 
Monday, July 25, 2022
Biotechnology, Consulting, Health, Professional Services, Small Business, CA, DNA, KKR, Brain, Strategic planning, Investment, Skin, Eye, Harvard University, MIT, SALT, Genome, Industry, OSI, HSV, CEO, IP, Board, Therapy, Sangamo Therapeutics, Paul Ruddock, Virology, Adoption, EVP, Pfizer, Technology, Library, Precision medicine, Bristol Myers Squibb, ONI, Software as a service, VC, Synthetic biology, AAV, Financial services, Pharmaceutical industry, Replay, Axial

DeciBio Ventures, a venture capital firm investing in and advising precision medicine start-ups, invested in the seed funding round for Replay.

Key Points: 
  • DeciBio Ventures, a venture capital firm investing in and advising precision medicine start-ups, invested in the seed funding round for Replay.
  • KKR & Co. Inc. and OMX Ventures led this funding round, which totaled $55 million.
  • As part of DeciBio Ventures strategy-heavy and supportive VC model, DeciBio Ventures is also providing Replay with ongoing strategic support.
  • Beyond Replays advanced technologies, DeciBio Ventures was drawn to Replays uniquely seasoned management team, founders, and Board members.

Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA

Retrieved on: 
Monday, July 25, 2022
MIT, Genome, MMS, Gene, Retirement, Sangamo Therapeutics, Late, Biological engineering, Pfizer, Company, LinkedIn, Biology, Professor, Brain, Investment, Skin, Eye, OSI, KKR, Doctor of Philosophy, Independent Board for Presbyterian Foreign Missions, Adverum Biotechnologies, Biotechnology, Technology, Library, Life, Growth, AAV, DNA, Insurance, SALT, Industry, Twitter, Neuroscience, CEO, Board, OMX, ONI, Therapy, Synthetic biology, Medicine, Science Publishing Group, CA, Massachusetts Institute of Technology, University, HSV, NYSE, Paul Ruddock, University of California, Berkeley, Stanford School, Senior advisor, Bristol Myers Squibb, Writing, Vaccine, Management, Cryptocurrency, Pharmaceutical industry, Fine chemical, Financial services, Microbiology, Research, Replay, Axial, Ophthalmology, MD

Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.

Key Points: 
  • Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.
  • Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.
  • Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA.
  • The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality.

Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA

Retrieved on: 
Monday, July 25, 2022
MIT, Genome, MMS, Gene, Retirement, Sangamo Therapeutics, Late, Biological engineering, Pfizer, Company, LinkedIn, Biology, Professor, Brain, Investment, Skin, Eye, OSI, KKR, Doctor of Philosophy, Independent Board for Presbyterian Foreign Missions, Adverum Biotechnologies, Biotechnology, Technology, Library, Life, Growth, AAV, DNA, Insurance, SALT, Industry, Twitter, Neuroscience, CEO, Board, OMX, ONI, Therapy, Synthetic biology, Medicine, Science Publishing Group, CA, Massachusetts Institute of Technology, University, HSV, NYSE, Paul Ruddock, University of California, Berkeley, Stanford School, Senior advisor, Bristol Myers Squibb, Writing, Vaccine, Management, Cryptocurrency, Pharmaceutical industry, Fine chemical, Financial services, Microbiology, Research, Replay, Axial, Ophthalmology, MD

Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.

Key Points: 
  • Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.
  • Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.
  • Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA.
  • The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality.

WIMI Hologram Academy: Vision-based Human-Computer Gesture Interaction Technology in Virtual Reality

Retrieved on: 
Monday, July 18, 2022
Learning, Research, AdaBoost, Acquisition, Arm, Hand, Method, Interaction, Communication, Machine learning, YCbCr, GLOBE, Science, Technology, YUV, AI, Support-vector machine, HSV, Classification, Hidden Markov model, SIFT, Probability, VR, Motion, NASDAQ, Observation, Gesture, Algorithm, Color, Histogram, Histogram of oriented gradients, Partnership, Virtual reality, Markov, Lighting, RGB, HOG, Security printing, Video game

(NASDAQ: WIMI)discussed a new technology in virtual reality interaction: vision-based human-computer gesture interaction technology.

Key Points: 
  • (NASDAQ: WIMI)discussed a new technology in virtual reality interaction: vision-based human-computer gesture interaction technology.
  • As an important part of human-computer interaction, vision-based gesture interaction is important for realizing natural interaction between human and VR virtual environment.
  • Gesture recognition is a key technology for gesture interaction, which directly affects the effect of gesture interaction and plays a pivotal role in the whole interaction process.
  • With the increasing demand for immersive experience in virtual reality, visual-based gesture interaction will certainly play an important role in virtual reality.

Rational Vaccines Herpes Simplex Type 2 (HSV-2) Therapeutic Vaccine Candidate Demonstrates Efficacy in a Therapeutic Animal Study

Retrieved on: 
Friday, July 8, 2022
Diagnosis, Mouse, Fever, Blister, Patient, School, Biotechnology, Nerve agent, Fissure, Severe cognitive impairment, UC Davis School of Veterinary Medicine, Disease, Louisiana State University, Chills, Erythema, Infection, Company, National, LSU, Simplex, Ulcer, Veterinary medicine, Virology, Guinea, NIH, World, WHO, Western world, Genital herpes, World Health Organization, Myalgia, Virus, Human, Animal, Neonatal infection, Vaccine, Foundation for the National Institutes of Health, HSV-2, HSV, Pharmaceutical industry

WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2). Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo. In addition, RVX201 appears to generate a robust cellular immune response equivalent to that elicited by wild-type HSV-2 on Day 7 post-infection. Results showed that in comparison to no vaccine, animals that received RVX201 had the number of symptomatic days reduced by 45 percent while those that received gD2-alum/MPL vaccine only had a 24 percent reduction in symptomatic days.

Key Points: 
  • and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2).
  • Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo.
  • The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
  • Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates.